Oxygen therapy limiting peripheral oxygen saturation to 89‐93% is associated with a better survival prognosis for critically ill COVID‐19 patients at high altitudes

dc.contributor.authorChristian Arias‐Reyes
dc.contributor.authorAntonio Viruez‐Soto
dc.contributor.authorSamuel Arias
dc.contributor.authorRonnie Casas‐Mamani
dc.contributor.authorGabriel Rada‐Barrera
dc.contributor.authorAlfredo Merino‐Luna
dc.contributor.authorDaniel Molano‐Franco
dc.contributor.authorAmílcar Tinoco-Solórzano
dc.contributor.authorDanuzia A. Marques
dc.contributor.authorNatalia Zubieta‐DeUrioste
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T18:41:10Z
dc.date.available2026-03-22T18:41:10Z
dc.date.issued2022
dc.description.abstractPatients admitted to the Intensive Care Unit (ICU) with acute hypoxemic respiratory failure automatically receive oxygen therapy to improve inspiratory oxygen fraction (FiO 2 ). Supplemental oxygen is the most prescribed drug for critically ill patients regardless of altitude of residence. In high altitude dwellers (i.e. in La Paz [»3,400 m] and El Alto [»4,150 m] in Bolivia), a peripheral oxygen saturation (SatpO 2 ) of 89‐95% and an arterial partial pressure of oxygen (PaO 2 ) of 50‐67mmHg (lower as altitude rises), are considered normal values for arterial blood. Consequently, it has been suggested that limiting oxygen therapy to maintain SatpO 2 around normoxia may help avoid episodes of hypoxemia, hyperoxemia, intermittent hypoxemia, and ultimately, mortality. In this study, we evaluated the impact of oxygen therapy on the mortality of critically ill COVID‐19 patients who permanently live at high altitudes. A multicenter cross‐sectional descriptive observational study was performed on 100 patients admitted to the ICU at the “Clinica Los Andes” (in La Paz city) and “Agramont” and “Del Norte” Hospitals (in El Alto city). Our results show that: 1) as expected, fatal cases were detected only in patients who required intubation and connection to invasive mechanical ventilation as a last resort to overcome their life‐threatening desaturation; 2) among intubated patients, prolonged periods in normoxia are associated with survival, prolonged periods in hypoxemia are associated with death, and time spent in hyperoxemia shows no association with survival or mortality; 3) the oxygenation limits required to effectively support the intubated patients’ survival in the ICU are between 89% and 93%; 4) among intubated patients with similar periods of normoxemic oxygenation, those with better SOFA scores survive; and 5) a lower frequency of observable reoxygenation events is not associated with survival. In conclusion, our findings indicate that high‐altitude patients entering an ICU at altitudes of 3,400 – 4,150 m should undergo oxygen therapy to maintain oxygenation levels between 89 and 93 %.
dc.identifier.doi10.1096/fasebj.2022.36.s1.l7958
dc.identifier.urihttps://doi.org/10.1096/fasebj.2022.36.s1.l7958
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/71581
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofThe FASEB Journal
dc.sourceUniversité Laval
dc.subjectHypoxemia
dc.subjectMedicine
dc.subjectFraction of inspired oxygen
dc.subjectOxygen therapy
dc.subjectOxygen saturation
dc.subjectIntensive care unit
dc.subjectMechanical ventilation
dc.subjectHypoxia (environmental)
dc.subjectEffects of high altitude on humans
dc.subjectAnesthesia
dc.titleOxygen therapy limiting peripheral oxygen saturation to 89‐93% is associated with a better survival prognosis for critically ill COVID‐19 patients at high altitudes
dc.typearticle

Files